For diagnosis of suspected hematopoietic tumors or monitoring of an established diagnosis, the Hematopathology Protocol (for bone marrow or tissue samples) and the Path Review with Reflex Flow Cytometry and Genomics (for peripheral blood samples) allows an expert hematopathologist to first review the sample morphology and then, following analysis by flow cytometry and other techniques as appropriate, the hematopathologist will order any additional molecular or cytogenetic testing that is indicated for diagnosis confirmation, risk stratification, or targeted treatment selection. Utilizing the these order options ensures that molecular and cytogenetic assays are initiated efficiently and effectively and eliminates the need for the clinical team to decide on ancillary testing before the lineage or degree of disease involvement is known.
Karyotyping and fluorescence in situ hybridization techniques are available for chromosome analysis of both hematopoietic and select solid tumors. Details of available FISH probes and panels as well as specimens accepted can be found here:
Using various techniques, including qPCR and Next Generation Sequencing (NGS), several single-gene targeted mutation assays, single fusion detection assays, and larger targeted mutation and fusion panels are available to characterize both hematopoietic and solid tumors, including high-sensitivity assays for the detection of measurable (minimal) residual disease in select cases of AML.
Full Targeted Oncology Testing Menu
Selected Assay Details:
